In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2

被引:19
作者
Su, Li [1 ]
Xu, Xun [1 ]
Zhao, Hui [1 ]
Gu, Qing [1 ]
Zou, Haidong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai 200080, Peoples R China
关键词
Tissue-type plasminogen activator; Kringle domain; Peptide; Angiogenesis inhibitor; ENDOTHELIAL-CELL MIGRATION; TUMOR-GROWTH; ANGIOGENESIS INHIBITOR; RETINAL NEOVASCULARIZATION; ALPHA(2)BETA(1) INTEGRINS; HUMAN APOLIPOPROTEIN(A); DOMAIN; ALPHA(1)BETA(1); DRUGS; TK1-2;
D O I
10.1016/j.bbrc.2010.05.048
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
A synthetic deca-peptide corresponding to the amino acid sequence Arg(54)-Trp(63) of human tissue-type plasminogen activator (t-PA) kringle 2 domain, named TKII-10, is produced and tested for its ability to inhibit endothelial cell proliferation, migration, tube formation in vitro, and angiogenesis in vivo. At the same time, another peptide TKII-10S composed of the same 10 amino acids as TKII-10, but in a different sequence, is also produced and tested. The results show that TKII-10 potently inhibits VEGF-stimulated endothelial cell migration and tube formation in a dose-dependent, as well as sequence-dependent, manner in vitro while it is inactive in inhibiting endothelial cell proliferation. Furthermore, TKII-10 potently inhibits angiogenesis in chick chorioallantoic membrane and mouse cornea. The middle four amino acids DGDA in their sequence play an important role in TKII-10 angiogenesis inhibition. These results suggest that TKII-10 is a novel angiogenesis inhibitor that may serve as a prototype for antiangiogenic drug development. (C) 2010 Published by Elsevier Inc.
引用
收藏
页码:1012 / 1017
页数:6
相关论文
共 26 条
[1]
A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo [J].
Bainbridge, JWB ;
Jia, HY ;
Bagherzadeh, A ;
Selwood, D ;
Ali, RR ;
Zachary, I .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 302 (04) :793-799
[2]
Cao Yihai, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P667, DOI 10.2174/1568011023353705
[3]
Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2 [J].
Carroll, VA ;
Nikitenko, LL ;
Bicknell, R ;
Harris, AL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (04) :736-741
[4]
Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo [J].
Cattaneo, MG ;
Pola, S ;
Francescato, P ;
Chillemi, F ;
Vicentini, LM .
EXPERIMENTAL CELL RESEARCH, 2003, 283 (02) :230-236
[5]
ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[6]
Kang BH, 2006, INT J ONCOL, V28, P361
[7]
Mechanisms of angiogenesis [J].
Karamysheva, A. F. .
BIOCHEMISTRY-MOSCOW, 2008, 73 (07) :751-762
[8]
Inhibition of endothelial cell proliferation by the recombinant kringle domain of tissue-type plasminogen activator [J].
Kim, HK ;
Lee, SY ;
Oh, HK ;
Kang, BH ;
Ku, HJ ;
Lee, Y ;
Shin, JY ;
Hong, YK ;
Joe, YA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (04) :740-746
[9]
Antimigratory effect of TK1-2 is mediated in part by interfering with integrin α2β1 [J].
Kim, Hyun-Kyung ;
Oh, Dae-Shik ;
Lee, Sang-Bae ;
Ha, Jung-Min ;
Joe, Young Ae .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) :2133-2141
[10]
DGDA, a local sequence of the kringle 2 domain, is a functional motif of the tissue-type plasminogen activator's antiangiogenic kringle domain [J].
Kim, Hyun-Kyung ;
Joe, Young Ae .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 391 (01) :166-169